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Abstract 
The Na+-dependent phosphate transporter NaPi-IIa (SLC34A1) is mostly 
expressed in kidney whereas NaPi-IIb (SLC34A2) has a wider tissue distribution with 
prominent expression in lung and small intestine. NaPi-IIa is involved in renal 
reabsorption of inorganic phosphate (Pi) from urine and patients with biallelic 
inactivating mutations in SLC34A1 develop hypophosphatemia, hypercalcemia, 
hypercalciuria and nephrocalcinosis and –lithiasis in early childhood. Monoallelic 
mutations are frequent in the general population and may impact on the risk to develop 
kidney stones in adulthood. SNPs in close vicinity to the SLC34A1 locus associate with 
the risk to develop CKD. NaPi-IIb mediates high-affinity transport of Pi from the diet and 
appears to be mostly important during low Pi availability. Biallelic inactivating SLC34A2 
mutations are found in patients with pulmonary alveolar microlithiasis, a lung disease 
characterized by the deposition of microcrystals. In contrast, no evidence for disturbed 
systemic Pi homeostasis has been reported in these patients to date. Nevertheless, 
NaPi-IIb mediated intestinal Pi absorption may be a target for pharmaceutical 
interventions in patients with chronic kidney disease and Pi overload. 
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Introduction 
 Phosphate is critical for life.  It is required for the synthesis of membrane lipids, 
DNA and RNA molecules, it forms part of energy rich molecules such as ATP or GTP, it 
is involved in phosphorylation/dephosphorylation reactions regulating protein activity, 
and it is a component of apatite giving stability to bone.  
In the 21st century, we live in an environment of dietary phosphate excess; 
however, meeting phosphate needs was not always simple and human beings, along 
with most organisms, evolved mechanisms to ensure adequate absorption of phosphate 
from their environment.  Being a multi-cellular, multi-organ organism, these mechanisms 
had to meet both total body homeostasis as well as unitary cellular needs.  Renal NaPi-
IIa and intestinal Napi-IIb, the first two members of the SLC34 family of sodium 
dependent phosphate cotransporters discovered, are critical for maintaining total body 
phosphate homeostasis, NaPi-IIa through regulation of renal excretion and NaPi-IIb 
through contribution to gastrointestinal absorption.  They are both responsible for 
initiating the transepithelial transport of phosphate, with lesser primary roles in the 
maintenance of cellular phosphate requirements.  However, the function of these two 
transporters ultimately has an impact on cellular phosphate availability and metabolism 
and of course on skeletal development and maintenance.  The impact of these two 
transporters on human physiology is revealed when their function is disrupted as 
reviewed here. The normal physiology of NaPi-IIa and NaPi-IIb will be briefly reviewed 
followed by a discussion of primary and secondary disorders affecting these 
transporters. 
 
NaPi-IIa (SLC34A1) 
Normal physiology 
 NaPi-IIa is an electrogenic sodium dependent phosphate transporter mediating 
the cotransport of 3 Na+ with one H2PO4- per transport cycle [25]. It is expressed almost 
exclusively in the apical membrane of the proximal renal tubule where it is responsible 
for the regulated reabsorption of filtered phosphate.  This function is shared with at least 
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two other sodium dependent phosphate transporters, NaPi-IIc (SLC34A3) and Pit2 
(SLC20A2) [4,96]. It has been estimated based on a Slc34a1 KO mouse model that 
NaPi-IIa mediates about 70 % of the reabsorption of phosphate from the ultrafiltrate [2]. 
Prior studies had suggested expression also in osteoblasts [101], osteoclasts [50], and 
odontoblasts [64]; however, the expression in osteoclasts appears to be very low and of 
little physiological relevance [1] and overall these studies performed in rodents have not 
been replicated in humans.   
In rodents, NaPi-IIa protein appears later in renal development than NaPi-IIc and 
continues to increase in expression through the first few weeks of life.  NaPi-IIc 
expression is highest in newborn animals and declines progressively through aging. 
Thus, it is thought that NaPi-IIa is the major renal phosphate transporter in adulthood. 
Whether this is also true for humans has remained unknown but recent evidence from 
genetics may suggest otherwise as discussed below.  
The ontogeny of human NaPi-IIa appearance has not been determined; however, 
studies in premature babies suggest suboptimal renal tubular phosphorus reabsorption 
in very premature infants, 25 weeks or less, but relatively intact renal phosphorus 
handling in older premature infants.  Overall the findings suggest that tubular 
phosphorus handling matures during the third trimester, implying that this is the time 
when the transporters appear, including NaPi-IIa. 
 Other than age, NaPi-IIa expression is regulated primarily by dietary phosphate 
intake and the hormones parathyroid hormone (PTH) and fibroblast growth factor 23 
(FGF23) [41].  Low dietary phosphate or malabsorption syndromes resulting in poor 
phosphate gastrointestinal uptake increase NaPi-IIa expression while high dietary 
phosphate downregulates NaPi-IIa expression [5].  The major phosphaturic hormones, 
PTH and FGF23, both downregulate the apical membrane expression of NaPi-IIa 
facilitating the urinary excretion of excessive dietary phosphate intake.  PTH secretion is 
regulated physiologically by ionized calcium concentrations but also affects phosphate 
handling, while FGF23 secretion is regulated predominantly by serum phosphate 
through unknown mechanisms. FGF23 downregulation of renal tubular phosphate 
absorption requires its cofactor, α-klotho [36].  
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Human disease associated with NaPi-IIa (SLC34A1) mutations 
 Mutations in SLC34A1 have been associated with various related diseases both 
in children and adults. Whereas there is increasing evidence for a role of monoallelic 
SLC34A1 mutations in adult kidney stone disease, findings from many families with 
biallelic inactivating mutations in SLC34A1 demonstrate a critical role of NaPi-IIa in 
intrauterine and postnatal renal phosphate handling.  
Urinary Pi wasting is part of generalized inherited or acquired syndromes of 
dysfunction of the proximal tubule (Debre-DeToni-Fanconi syndrome). Here, we will 
concentrate on disturbances that are primarily caused by mutations in SLC34A1. 
Mutations in both SLC34A1 and SLC34A3 result in renal phosphate wasting and 
nephrocalcinosis and –lithiasis, but the clinical pictures differ in that rickets is a major 
manifestation of SLC34A3 but not SLC34A1 mutations [4].  
 Genome wide studies (GWAS) have associated SLC34A1 with serum Pi [48], 
kidney stones [105,95,72], hypophosphatemia and low PTH [74], PTH levels in general 
[84], FGF23 levels [83], risk for chronic kidney disease (see also below [55,56,76,68]), 
and salt-sensitive hypertension [68].  The biology behind these associations is in part 
well explained (see below) but in some cases remains to be fully established, i.e. for 
CKD and salt-sensitive hypertension. 
 Monoallelic SLC34A1 mutations have been identified in adult patients with kidney 
stones and reduced bone density [78], whereas biallelic mutations were found in 
children with either hypophosphatemia and hyperphosphaturia [81], or with infantile 
idiopathic hypercalciuria [88] or with nephrocalcinosis and kidney stones 
[7,74,30,19,67,38]. Patients from one large family with a 21-nucleotide insertion in the 
transporter also showed symptoms of a more generalized proximal tubular dysfunction 
with unusually high calcitriol levels atypical for Fanconi-like syndromes [67,17]. In some 
cases, associations were present with metabolic acidosis or epilepsy, sensorineural 
deafness and learning deficiencies which may not be directly linked to mutations in 
SLC34A1 [23]. Large deletions encompassing SLC34A1 are found in patients with 
Sotos syndrome with learning deficiencies, facial dysmorphia, overgrowth, 
hypercalcemia, and nephrocalcinosis [47].  
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In pediatric patients, SLC34A1 mutations are mostly homozygous or compound 
heterozygous with clinical symptoms showing an autosomal recessive inheritance. 
Thirty mutated sites have been identified in SLC34A1, mostly causing missense 
mutations, small in-frame deletions, frame shifts or early stop-codons 
[74,7,19,30,67,78,81,79,17,38,57]. Many of these mutations are located within the 
predicted highly conserved transmembrane domains of the transporter possibly 
disturbing folding and/or stability of the protein in the membrane. Consistently, the 
functional analysis of several of these mutants demonstrated function possibly due to 
trafficking defects with intracellular retention of the mutant protein [88,81,19,17,23].  
An in-frame deletion of 7 amino acids at the cytoplasmic N-terminal tail (91del7) 
is of particular interest. The mutation has been detected in several patients either in 
compound heterozygosity or in homozygosity [88,23,38]. The clinical symptoms of 
homozygous and compound heterozygous patients are similar to patients carrying other 
SLC34A1 mutations strongly suggesting that the 91del7 mutation is fully pathogenic. 
However, functional studies provide evidence for only a very mild transport defect 
[88,60,23] with only little reduction in apical expression consistent with a possible 
trafficking defect [88]. Of interest, this mutation has a high minor allele frequency of 
0.018 (ExAC http://exac.broadinstitute.org/) suggesting that nearly 2 % of the general 
population carries this mutation on one allele. Moreover, the combined allele frequency 
of all pathogenic exonic mutations tested to date is 0.022 and the total allele frequency 
of all nucleotide changes causing alterations in the amino acid sequence sums even up 
to 0.07. It is currently unknown why SLC34A1 mutations have accumulated such a high 
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frequency, whether there has been any advantage during evolution associated with 
such mutations, and what the clinical consequences of such mutations may be. As 
discussed below, evidence is emerging that monoallelic mutations may be associated 
with the risk for kidney stones in adulthood.    
 
SLC34A1 and adult stone formers 
Prie et al reported two adult patients with stone disease, reduced bone mineral 
density and monoallelic SLC34A1 mutations [78]. Unfortunately, no further family data 
were available testing for segregation of the phenotype with the mutations. When NaPi-
IIa constructs expressing these mutations were expressed in Xenopus oocytes, the 
stimulated phosphate uptake was significantly less than with wild type suggesting that 
these mutations rendered tubular phosphate reabsorption less resulting in 
nephrolithiasis or decreased bone mass.  An in depth analysis of the effect of these 
mutations on phosphate transport kinetics, affinity, and transporter localization by Virkki 
et al [97] confirmed the slightly decreased phosphate transport by the NaPi-IIa mutants 
but did not disclose any differences in affinity, pH dependence, voltage dependence, or 
transporter turnover.  It remained unclear whether the 30% decrease in transport was 
sufficient to explain the clinical presentation of the two subjects. Similarly, LaPointe and 
coworkers [60] explored the association between hypophosphatemic, hypercalciuric 
stone formation and NaPi-IIa mutations further by sequencing the gene in 28 
individuals, investigating affected and unaffected family members for gene variations, 
and expressing the NaPi-IIa constructs in oocytes and opossum (OK) cells.  They 
identified 5 polymorphisms but failed to find a correlation between the presence of a 
polymorphism and phosphate wasting within families.  When expressed in oocytes, 
phosphate transport was diminished for some but not all of the genetic variants.  They 
concluded that their study did not support a role for altered NaPi-IIa function as 
causative for stones. 
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A major problem in these studies is that stone disease and its association with 
reduced bone density is highly frequent (up to 10 %) in the adult population. 
Nevertheless, also GWAS clearly support a role of SLC34A1 in stone disease 
[74,95,105]. NaPi-IIa forms homodimers [28] witht both subunits functioning 
independently [54]. One might speculate that monoallelic mutations either impair the 
trafficking of dimers of wildtype and mutant protein causing a dominant negative effect 
or that the function of one normal allele may not be enough to adapt renal Pi handling to 
changing metabolic and dietary demands. 
 
Pathophysiology of nephrolithiasis and -calcinosis 
The pathophysiology leading to hypercalciuria and nephrolithiasis and –
calcinosis has been examined using the Slc34a1 KO mice [51,2,88]. These experiments 
together with the clinical symptoms and biochemical changes in patients with SLC34A1 
mutations suggest the renal loss of phosphate and the subsequent development of 
hypophosphatemia reduce FGF23 levels. Low plasma phosphate and low FGF23 
stimulate the activity of the CYP27B1 enzyme mediating the final 1-a-hydroxylation of 
25-OH vitamin D3 to the active 1,25-(OH)2 vitamin D3 (calcitriol). Also, the activity of 
the CYP24A1 enzyme inactivating calcitriol is reduced [88]. High calcitriol levels 
stimulate intestinal phosphate absorption via NaPi-IIb[11] but also intestinal calcium 
absorption [13]. The inappropriately high calcium absorption leads to hypercalcemia and 
hypercalciuria. In urine, high calcium triggers precipitations with phosphate and/or 
oxalate causing nephrocalcinosis or –lithiasis.  
A recent study also demonstrated that Slc34a1 knock out mice showed 
diminished renal excretion of osteopontin, a protein that binds calcium and reduces 
calcium crystallization, and that the combination of Slc34a1 and osteopontin deletion 
magnified the tendency toward renal mineralization [10].  Osteopontin production is 
stimulated by FGF23, suggesting that the mechanism for the nephrocalcinosis seen in 
phosphate wasting states may be due to reduced FGF23 production leading to reduced 
renal excretion of osteopontin and loss of the antagonistic effect on crystal formation.   
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Fearn et al [23] reported two patients with a clinical picture different from what 
has been found in most patients. The first patient was heterozygous whereas the 
second was compound homozygous for SLC34A1 mutations. Both patients had stone 
disease, the first patient had also deafness, learning difficulties, CKD stage 4 with low 
calcitriol and high FGF23 levels. The second patient had pronounced nephrocalcinosis 
with metabolic acidosis, low calcitriol and high FGF23 concentrations.  From a clinical 
standpoint, these cases also presented an interesting paradox.  Although primary 
phosphate wasting syndromes have been associated with low FGF23 and high active 
vitamin D levels, the two individuals studied in this paper had the opposite.  Although 
the authors hypothesized that the severely ill condition of the subjects accounted for the 
elevated FGF23 levels through the development of inflammation, another stimulator of 
FGF23, these cases point out some of the difficulties in the clinical identification of 
affected individuals, the role of specific SLC34A1 variants in the clinical picture, and the 
contribution of FGF23 and vitamin D to the disease manifestations. 
 
NaPi-IIa and chronic kidney disease 
 Genome-wide association studies (GWAS) have identified more than 100 risk 
loci in the human genome associated with a higher risk for developing chronic kidney 
disease [56,76,55,68]. Consistently, associations were found for markers next to the 
gene locus harboring SLC34A1 with significant odds ratios for developing CKD between 
1.05 and 1.10 in a cohort of European and mixed Asian, African and European descent, 
respectively [18]. However, none of these markers resides within the coding region of 
SLC34A1 and no studies have been undertaken to test the impact of these SNPs on 
SLC34A1 expression. Thus, the pathophysiological and clinical relevance of these 
SNPs remains to be elucidated. A recent study linked lower mRNA expression levels of 
NaPi-IIa in kidney biopsies from patients with CKD to the risk of developing CKD 
because of low NaPi-IIa abundance [62]. Whether the reduction of NaPI-IIa mRNA is 
cause or consequence in these patients is unclear and low NaPi-IIa mRNA may simply 
reflect lower nephron mass or reduced expression due to high FGF23 and PTH levels.   
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Mutations in hormones and proteins regulating NaPi-IIa 
Mutations in the hormones and proteins regulating NaPi-IIa expression and function will 
also result in clinical disease.  These will be discussed briefly. For a more extensive 
review the reader is referred to several recent reviews [99,100,3]. 
 Hypophosphatemia and renal phosphate wasting due hyperparathroidism can be 
the result of inactivating mutations in the calcium sensing receptor (CaSR), the G-alpha 
11 protein (GNA11), the clathrin adaptor protein AP2 (AP2S1), the tumor suppressor 
menin (MEN1), the cyclin dependent kinase inhibitor (CDKN1B), parafibromin (CDC73), 
or activating mutations of the proto-oncogene RET (RET) or the chorion specific 
transcription factor (GCM2) [70].  Clinically these syndromes are frequently dominated 
more by the presence of hypercalcemia than by abnormalities in phosphate metabolism.  
In contrast, several gene mutations associated with rare syndromes of 
hypoparathyroidism can produce hyperphosphatemia (reviewed in:  [14]).  The rare 
syndrome of pseudohypoparathyroidism is also associated with hyperphosphatemia 
due to renal resistance to the phosphaturic effect of parathyroid hormone [14,90], 
resulting from mutations in the alpha subunit of the stimulatory G protein Gαs.  
Elevations in FGF23 also cause hypophosphatemia due to downregulation of 
NaPi-IIa and suppression of calcitriol levels. High FGF23 can be caused by mutations in 
the protein itself preventing its cleavage (autosomal dominant hypophosphatemic 
rickets), mutations in PHEX (phosphate regulating gene with homologies to 
endopeptidases, X-linked hypophosphatemic rickets), Dentin Matrix Protein (DMP1), 
ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), or FAM20C (Family 
with sequence similarity 20C), for which inactivating mutations can produce autosomal 
recessive hypophosphatemic rickets (reviewed in [21]).   
Syndromes associated with high FGF23 levels can be distinguished from 
hyperparathyroid syndromes clinically by the absence of hypercalcemia and the normal 
or low active 1,25-(OH)2 vitamin D3 levels.  In contrast, genetic conditions leading to low 
FGF23 levels or function cause hyperphosphatemia.  These rare syndromes, all entitled 
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tumoral calcinosis, encompass inactivating mutations in GALNT3 (UDP-N-acetyl-alpha-
D-galactosamine:polypeptide N-acetylgalactos-aminyl transferase-3), an enzyme that 
O-glycosylates FGF23 and prevents excessive cleavage of the protein; mutations in 
FGF23 that result in excessive cleavage of FGF23 protein; and inactivating mutations in 
a-Klotho, leading to the inability of FGF23 to activate its cognate receptors.  
PDZ domain proteins play a central role in NaPi-IIa trafficking and localization 
[31].  Karim and coworkers  described three mutations in the protein NHERF1 (Na-H 
Exchanger Regulatory Factor, Isoform 1) associated with decreased tubular 
reabsorption of phosphate and low bone mineral and/or nephrolithiasis [43].  These 
heterozygous mutations resulted in enhanced responsiveness to parathyroid hormone 
in a cell culture model, leading to lower phosphate transport rates.  Urinary cAMP 
excretion, a marker of PTH effects, was higher in individuals expressing the NHERF1 
mutations. However, SNPs in NHERF-1 are frequent in the general population and their 
relevance for renal phosphate handling are currently unknown. 
 
NaPi-IIb (SLC34A2) 
Physiology of NaPi-IIb 
NaPi-IIb (SLC34A2) was initially cloned from small intestine [34] where it is 
expressed at the apical side of enterocytes lining the small intestine. Considerable 
species differences exist between mice, rats and humans. In mice, NaPi-IIb is mostly 
expressed in ileum whereas in rats and humans, NaPi-IIb is expressed in duodenum 
and jejunum but is absent from ileum [27,69,80]. The physiological relevance of this 
difference is not known. NaPi-IIb is an electrogenic Na+-phosphate cotransporter 
coupling the transport of 3 Na+ to the transfer of one H2PO42-. Its transport mechanism 
has been reviewed in detail elsewhere [25]. The apparent affinities for Na+ and 
phosphate are around 25 mM and 10 μM, respectively [25]. The high affinity for 
phosphate may suggest that the cotransporter is easily saturated at normal intestinal 
phosphate concentrations and may be more important during times of low phosphate 
availability.  
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NaPi-IIb is found in several organs outside of the small intestine including testis, 
mammary glands, salivary glands, and lung. While the role in testis has not been 
examined, NaPi-IIb is involved in mediating secretion of phosphate into milk and saliva, 
respectively [35,73]. In lung, NaPi-IIb is expressed in type II alveolar cells and may play 
a role in controlling phosphate levels in the intraalveolar fluid [93,86]. 
Regulated expression and activity of NaPi-IIb has been best examined for the 
small intestine. There, NaPi-IIb is regulated by dietary phosphate intake. While high 
phosphate intake downregulates NaPi-IIb protein abundance, low phosphate availability 
stimulates NaPi-IIb expression [80]. Also, 1,25-(OH)2 vitamin D3 stimulates NaPi-IIb 
expression through the Vitamin D receptor (VDR). Nevertheless, the adaption of NaPi-
IIb to dietary phisphate intake does neither require 1,25-(OH)2 vitamin D3 nor the VDR 
[11]. Also estrogens stimulate NaPi-IIb expression [104] whereas epidermal growth 
factor (EGF) appears to reduce expression [103]. 
For a more detailed review on the regulation of NaPi-IIb in the intestine the 
reader is referred to a recent review [33]. 
 
Human disease associated with NaPi-IIb (SLC34A2) mutations 
Homozygous and compound heterozygous mutations in SLC34A2 have been 
detected in patients with pulmonary alveolar microlithiasis (PAM), a disease 
characterized by progressive deposition of calcium phosphate containing microcrystals 
in lung, inflammation, tissue destruction, pulmonary fibrosis and insufficiency, and cor 
pulmonale in some patients [15,24,37]. In a few patients, heterozygous mutations were 
linked to testicular microlithiasis but this has not been replicated by independent studies 
[15]. At present, 20 distinct mutations have been reported, including deletions, frame 
shifts, missense mutations as well as changes in potential splice sites and in the 
promoter region [15,98,37,40,89,42,102,106,20,66,75,39].  
The impact of these mutations on transport activity, trafficking or protein stability 
has not been well characterized. One study provided evidence that at least two 
truncated mutants do not transport Pi  upon expression in Xenopus oocytes [37]. 
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NaPi-IIb is expressed in lung in type II pneumocytes [93], cells important for surfactant 
production. The capacity of one SLC34A2 mutant to transport Pi after expression in an 
alveolar cell line was diminished suggesting that NaPi-IIb could play a role in controlling 
extracellular Pi levels in alveolar fluid   [65]. 
Despite the prominent expression of NaPi-IIb in intestine, no phenotype related to 
intestinal Pi absorption or systemic Pi homeostasis is known in patients with SLC34A2 
mutations. Several mouse models of Slc34a2 deletion have been generated, mostly to 
characterize the role of NaPi-IIb in intestine [32,85]. These models demonstrate that 
NaPi-IIb is the main cotransporter in the ileum, but its absence has only mild 
consequences on Pi and hormonal levels [53,32,85]. In contrast, a lung epithelium 
specific NaPi-IIb mouse had higher Pi concentrations in the bronchoalveolar fluid with 
microcrystals, invasion of macrophages and signs of inflammation and fibrosis [86]. 
Microcrystals were resolved by EDTA bronchoalveolar lavage or by placing mice on a 
low Pi diet for 4 weeks. The relevance of these experimental therapies remains to be 
tested in patients.  
 
Dysregulation of NaPi-IIb in disease 
 Inflammatory bowel disease 
Patients with inflammatory bowel disease are at risk to develop bone disease 
with low bone mineral density. Malabsorption of vitamin D3, calcium and phosphate can 
contribute to the risk. Inflammation has been shown to downregulate NaPi-IIb 
expression in a TNF-dependent manner [12]. In addition, TNF may also downregulate 
bone PHEX expression and thereby indirectly increase FGF23 levels which woukld 
reduce 1,25-(OH)2 Vitamin D3 dependent stimulation of NaPi-IIb expression [94].  
Chronic kidney disease 
In patients with chronic kidney disease, mineral metabolism is severely disturbed. 
The profile of hormones regulating mineral metabolism is altered. FGF23 rises whereas 
a-klotho 1,25-(OH)2-vitamin D3 fall early during the development of CKD [36,77]. Later 
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PTH is increased and eventually plasma phosphate elevated. The loss of functional 
nephrons progressively reduces the renal ability to excrete phosphate. Nevertheless, 
plasma phosphate remains within the normal range until CKD progresses to end‐stage 
renal disease (ESRD, stages 4 and 5), as remaining healthy nephrons compensate [8].  
Hyperphosphatemia is a major risk factor for all‐cause mortality in CKD patients 
[49,6] and. cardiovascular disease is the leading cause of mortality in this vulnerable 
population [9,29]. Thus, targeting hyperphosphatemia is of outmost importance in 
patients with CKD. Current strategies addressing hyperphosphatemia include restricted 
dietary phosphate intake together with phosphate binders [82]. More recently, 
pharmaceutical strategies were described targeting NaPi-IIb mediated intestinal 
phosphate absorption [26]. 
In uremic mice, the application of a phosphate bolus increased plasma 
phosphate and FGF23 despite the presence of a phosphate binder. This increase was 
blunted in mice with a conditional whole body deletion of NaPi-IIb also receiving a 
phosphate binder [87]. These data suggested that the combined reduction of freely 
absorbable phosphate with the inhibition of NaPi-IIb (i.e. the reduction of the 
paracellular pathway for phosphate and the inhibition of transcellular Pi transport) could 
be an effective strategy to lower phosphate loads in patients with reduced kidney 
function. 
Consistent with the lack of evidence for a systemic alteration of phosphate 
homeostasis, the direct inhibition of NaPi-IIb with a specific inhibitor has failed in a 
phase I and II study having no impact on plasma phosphate and FGF23 levels [61]. 
Unfortunately, no trial has been reported yet combining a NaPi-IIb specific inhibitor with 
phosphate binders. 
Nicotinamide and niacin have been reported to reduce NaPi-IIb expression and 
to lower plasma phosphate levels both in experimental animal studies and in small trials 
with patients with CKD [22,44,91]. The exact mechanism how these compounds reduce 
intestinal phosphate absorption is not fully clear. A common metabolite of both 
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substances is NAD+ which has been shown to directly (and maybe also indirectly) inhibit 
renal and intestinal Pi transport [46]. Very recent evidence suggests that NAD+ 
mediates at least in part the circadian regulation of renal and intestinal Pi transporters 
[71,92]. On-going clinical trials test the efficacy of nicotinamide in combination with 
conventional phosphate binders in the NOPHOS (EU Clinical Trials Register 2013-
000488-95) and COMBINE (ClinicalTrials.gov Identifier: NCT02258074) trials. 
Similarly, tenapanor, an inhibitor of the Na+/H+ exchanger isoform 3 (NHE3) 
reduces intestinal Pi absorption [58]. Initially, it had been speculated that tenapanor may 
also modulate NaPi-IIb activity and/or expression but recent data demonstrated that the 
substance acts on paracellular Pi fluxes without affecting active transcellular Pi 
transport [52]. 
 
NaPi-IIb and cancer 
Studies dating from the 1980s have suggested that NaPi-IIb can be used as a 
marker for specific tumors including ovarian and lung cancer, although the identity of 
NaPi-IIb as the marker was initially unknown (reviewed in [59]).  A monoclonal antibody 
was developed to identify epithelial tumors through binding to an antigen named MX35, 
which on further characterization was found to be NaPi-IIb [63]. In the tumors 
expressing NaPi-IIb, the protein has been identified as wild type; however, a recent 
phenomenon whereby SLC34A2 undergoes molecular re-arrangement with ROS-1, a 
tyrosine kinase receptor, to create a constitutively active tyrosine kinase that increases 
oncogenicity has been described [45,16].  Furthermore, there is some evidence that 
high expression of NaPi-IIb may confer resistance to cancer chemotherapy and may 
increase metastatic potential [59].   
 
Summary and outlook 
Phosphate is critical for many cellular and organ functions. Its absorption and 
excretion as well as its (re)distribution in the body depend at least in part on Na+-
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dependent phosphate transporters of the SLC34 gene family. It is thus not surprising 
that mutations in all three members of this family can cause distinct pathologies in 
humans. The high frequency of monoallelic mutations in SLC34A1 may have relevance 
for the susceptibility of adults to form kidney stones. The role of SLC34A1 in CKD risk 
remains to be explored as well as the role of SLC34A2 in cancer. If substantiated, NaPi-
IIa and NaPi-IIb may also become targets for pharmacological interventions in these 
diseases. Attempts to target NaPi-IIb in controlling hyperphosphatemia in patients with 
CKD have not been successful to date but may need to be combined with other 
approaches to lower bioavailable intestinal phosphate concentrations to be effective.  
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Figure legends 
 
Table 1 
Summary of diseases that have been proven to be caused by alterations in the function 
of SLC34A1 or SLC34A2 and diseases with associations with the two genes but where 
the causative relationship has not been well established yet. 
 
Figure 1 
Model explaining how reduced function of SLC34A1 (due to loss-of-function mutations 
or dysregulation) can cause dysregulation of hormones regulating mineral homeostasis 
and supports the development of nephrocalcinosis and -lithiasis. Red arrows and boxes 
indicate hormones or processes downregulated, green arrows and boxes indicate 
hormones or processes upregulated. For details, please see text. sHPO42- (serum 
phosphate), uHPO42- (urine phosphate), uCa2+ (urine calcium), sCa2+ (serum calcium)  
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Table 1:  SLC34A1 and SLC34A2 Mutations and Clinical Disease Associations 
 
Transporter Identified Disease Associations Implicated Clinical Associations 
SLC34A1 Osteopenia 
Nephrolithiasis 
Nephrocalcinosis 
Idiopathic Infantile Hypercalcemia 
Chronic Kidney Disease 
Salt Sensitive Hypertension 
Serum Phosphate Level 
Serum PTH Level 
Serum FGF23 Level 
 
SLC34A2 Pulmonary Alveolar Microlithiasis Cancer Metastasis and 
Chemotherapy Resistance 
 
1,25-(OH)2-D3
FGF23
sHPO42-
25-OH-D3Vit. D3 Calcitroic acid
uHPO42-
uCa2+
PTH
CYP27B1
Kidney stones
Nephrocalcinosis
CYP24A1
NaPi-IIa
(NaPi-IIc)
sCa2+
